Platinum(IV) prodrugs

Research output not available from this repository.

Request-a-Copy directly from author or use local Library Get it For Me service.

Request Changes to record.

Abstract

This chapter is an overview of recent progress in the design of Pt(IV) prodrugs. These kinetically-inert octahedral prodrugs can be reduced in cancer cells to active squareplanar Pt(II) complexes, for example by intracellular reducing agents such as glutathione or by photoexcitation. The additional axial ligands in Pt(IV) complexes which are released on reduction, allow bioactive molecules to be delivered which can act synergistically with Pt(II) in killing cancer cells, or act as targeting vectors, allow attachment to polymer and nanoparticle delivery systems, or labelling with fluorescent probes. Pt(IV) prodrugs have yet to be approved for clinical use, although some offer the promise of increased efficacy and reduced side effects.

Item Type: Book Item
Divisions: Faculty of Science, Engineering and Medicine > Science > Chemistry
Series Name: Metal Ions in Life Sciences
Publisher: De Gruyter
ISBN: 9783110470734
Book Title: Metallo-Drugs: Development and Action of Anticancer Agents
Editor: Sigel, Astrid and Sigel, Helmut and Freisinger, Eva and Sigel, Roland K.O.
Official Date: 2018
Dates:
Date
Event
2018
UNSPECIFIED
Volume: 18
Page Range: pp. 69-108
DOI: 10.1515/9783110470734-009
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
URI: https://wrap.warwick.ac.uk/101947/

Export / Share Citation


Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item